BRIEF-FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Reuters2026/09/24 19:21Sept 24 (Reuters) - FDA:
FDA APPROVES BELZUTIFAN IN COMBINATION WITH LENVATINIB FOR ADVANCED RENAL CELL CARCINOMA WITH A CLEAR CELL COMPONENT
FDA: RECOMMENDED DOSAGE IS 20 MG OF LENVATINIB IN COMBINATION WITH 120 MG OF BELZUTIFAN ONCE DAILY UNTIL DISEASE PROGRESSION OR UNACCEPTABLE TOXICITY
Further company coverage: MRK.N
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
British Pound trades lower against Japanese Yen amid intervention fears
Pi Network: Will mainnet KYC upgrades save PI crypto from drop to $0.076?
Why Is Tether Bringing USDT Back to Bitcoin Now? Morgan Stanley Offers a Clue
Swiss Franc: Dovish SNB keeps CHF under pressure against US Dollar – ING
Crypto prices
More
